GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bioceltix BCX.WA · PLN

Health Care · GPW · 🇵🇱 Poland

Compare

68.70

-0.43%

Close of 9 Nov 2026, in PLN

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bioceltix

Its shares trade on GPW under the ticker BCX.WA. It has been listed since 8 November 2021. In the fiscal year to 31 December 2020, it reported revenue of PLN 10,800 and a net loss of PLN 2.3m. At that date it held total assets of PLN 4.8m and shareholders' equity of PLN 3.3m.

Bioceltix SA engages in the research and development in the area of veterinary medicine. The company is headquartered in Wroclaw, Woj. Dolnoslaskie. The company went IPO on 2021-11-08. The firm deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The firm carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Nov 2021

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Bioceltix SA develops veterinary medicinal products using mesenchymal stem cells in Wroclaw, Poland.
  • The company's R&D focuses on immunomodulatory properties for companion animal treatments.
  • Bioceltix SA has completed clinical trials and registration with the European Medicines Agency.

Weaknesses

  • Bioceltix SA operates in a niche veterinary biotechnology sector with limited market size.
  • The company's product development cycle is lengthy due to regulatory requirements.
  • Bioceltix SA has no established commercial sales channels in the European market.

Opportunities

  • Growing demand for veterinary biotechnology solutions in the European Union.
  • Expansion into companion animal healthcare markets across Poland and neighboring countries.
  • Potential partnerships with European pharmaceutical companies for product distribution.

Threats

  • Regulatory changes in the European Medicines Agency could delay product approvals.
  • Competition from established veterinary pharmaceutical firms in the EU market.
  • Economic downturns may reduce spending on veterinary healthcare services.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.